Abstract
BackgroundPatterns of progressive disease (PD) in patients with local and metastatic sites of breast cancer are poorly described. Whole-body magnetic resonance imaging (WB-MRI) identifies PD earlier than CT. MethodsThirty-one patients receiving first-line systemic anti-cancer therapy (SACT) were studied. Data were obtained from original WB-MRI reports. ResultsFirst PD was reported at metastatic sites only in 77.4%, and at local and metastatic sites concurrently in 22.6%. None had first PD only in local disease, or clinical PD before PD on WB-MRI. ConclusionClinical evidence of SACT benefit in local disease may give false reassurance about disease at metastatic sites.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
